Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 22:10:20552076241282380.
doi: 10.1177/20552076241282380. eCollection 2024 Jan-Dec.

Observational study of the Amaze™ asthma disease management platform

Jehan Alladina  1 , Peter P Moschovis  2 , Hitesh N Gandhi  3 , Donna Carstens  3 , Elizabeth D Bacci  4 , Katelyn Cutts  5 , Karin S Coyne  5 , Karen Goldsborough  3 , Dawei Jiang  6 , Conor O'Brien  6 , T Bernard Kinane  2
Affiliations

Observational study of the Amaze™ asthma disease management platform

Jehan Alladina et al. Digit Health. .

Abstract

Objective: Asthma is often inadequately controlled, which can result in exacerbations that lead to unplanned healthcare visits. Mobile application (app) use could help manage asthma exacerbations. We implemented the Amaze™ asthma disease management platform in clinical practice and assessed user satisfaction, usage, and usability.

Methods: Adults with asthma and healthcare professionals (HCPs) were enrolled from a community allergy practice (ClinicalTrials.gov Identifier: NCT04901260) and a large academic hospital (ClinicalTrials.gov Identifier: NCT04868500). Primary and exploratory outcomes included assessment of platform design, patient app usage, patient-reported daily asthma status, emergency room/urgent care visits, and ease of implementation by HCPs. The system usability scale and a post-clinic visit survey were also administered. HCPs/staff monitored the Amaze dashboard to assess patient needs and completed a post-study survey.

Results: Overall, 159 patients and five HCPs participated in the study. Patients' mean (SD) age was 38.7 (16.4) years; most were female (78%) and White (78%). Mean patient app usage began at 3.6 days/week but declined to 1.0 day/week by the end of the study. Throughout the study, most daily entries (>69%) reported patient asthma status as "good." Most patients were satisfied/very satisfied with the app (66%) and reported it helped them during discussions with their HCP (44%). Most patients rated the usability of Amaze as "excellent" (49%) or "good" (30%). Most HCPs (71%) reported that Amaze was "very easy" to implement.

Conclusions: Most patients and HCPs were satisfied with Amaze. The Amaze platform may help patients and HCPs monitor asthma status, which could improve asthma control.

Keywords: Asthma management; digital technology; mobile health.

PubMed Disclaimer

Conflict of interest statement

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JA has received research funding from AstraZeneca and a grant from the National Institutes of Health (grant #5KL2TR002542-04). PPM has received a grant from the National Institutes of Health (grant #K23ES030399) and has served on an adjudication committee for Pfizer. HNG was an employee of AstraZeneca at the time this work was completed and is a current employee of Alexion (AstraZeneca Rare Disease). DC is an employee of AstraZeneca. KG was an employee of AstraZeneca at the time this work was completed. EDB, KC, and KSC are employees of Evidera, which was contracted by AstraZeneca to conduct this study. DJ, CO, and TBK have no relevant conflicts of interest to disclose. All listed authors approve the funding and conflict of interest disclosure statements.

Figures

Figure 1.
Figure 1.
Amaze app screenshots showing key features. (A) Patient app interface and (B) clinician dashboard.
Figure 2.
Figure 2.
Amaze patient usage per 4-week period (N = 153). The white boxes indicate mean number of entries per week.
Figure 3.
Figure 3.
End-of-study patient ratings for Amaze features (N = 77). Patients were asked to rate each feature of the app on a 5-star rating. Ratings ranged from 1 = poor to 5 = excellent.
Figure A.1.
Figure A.1.
Data disposition and study flow diagram.
Figure A.2.
Figure A.2.
Amaze clinical staff usage per 4-week period (N = 12).
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention, Uncontrolled asthma among adults. https://www.cdc.gov/asthma/asthma_stats/uncontrolled-asthma-adults.htm, 2016 (accessed August 5 2022).
    1. Demoly P, Annunziata K, Gubba Eet al. et al. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012; 21: 66–74. - PMC - PubMed
    1. Laforest L, Van Ganse E, Devouassoux G, et al. Asthmatic patients’ poor awareness of inadequate disease control: a pharmacy-based survey. Ann Allergy Asthma Immunol 2007; 98: 146–152. - PubMed
    1. Gelhorn HL, Ye X, Speck RM, et al. The measurement of physical functioning among patients with tenosynovial giant cell tumor (TGCT) using the patient-reported outcomes measurement information system (PROMIS). J Patient Rep Outcomes 2019; 3: 6. - PMC - PubMed
    1. Chapman KR, Boulet LP, Rea RMet al. et al. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31: 320–325. - PubMed

Associated data

LinkOut - more resources